Strategies for treatment to prevent fragility fractures in postmenopausal women

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 6, 2009, Pages 727-740

  Geusens, Piet ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Adherence; Case finding; Diagnosis; Postmenopausal osteoporosis; Safety; Tolerance; Treatment, fracture prevention

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; DENOSUMAB; ESTROGEN; GENERIC DRUG; GLUCOCORTICOID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ALGORITHM; BONE DENSITOMETRY; BONE DENSITY; BONE MINERALIZATION; BONE REMODELING; BREAST CANCER; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRESS SYNDROME; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGUS INJURY; FALLING; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; LEG CRAMP; LIFESTYLE MODIFICATION; MENOPAUSAL SYNDROME; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT MONITORING; PHYSICAL ACTIVITY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REIMBURSEMENT; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; THERAPEUTIC ERROR; TREATMENT DURATION; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RISK FACTORS;

EID: 71749098537     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.09.001     Document Type: Review

References (89)

1. Sambrook P., and Cooper C. Osteoporosis. Lancet 367 (2006) 2010-2018
2. Available at:. http://www.nof.org/professionals/NOF_GUIDE_OVERVIEW.pdf
3. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., and Oden A. National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 19 10 (2008 Oct) 1395-1408
4. Kanis J.A., Burlet N., Cooper C., Delmas P.D., Reginster J.Y., Borgstrom F., and Rizzoli R. European society for clinical and economic aspects of osteoporosis and osteoarthritis (esceo). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19 4 (2008) 399-428
5. Geusens P.P., Roux C.H., Reid D.M., Lems W.F., Adami S., Adachi J.D., Sambrook P.N., Saag K.G., Lane N.E., and Hochberg M.C. Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence-based clinical perspective. Nat Clin Pract Rheumatol 4 5 (2008) 240-248
6. Kanis J.A., Oden A., Johansson H., Borgström F., Ström O., and McCloskey E. FRAX((R)) and its applications to clinical practice. Bone 44 5 (2009) 734-743
7. Available at:. http://www.shef.ac.uk/FRAX/
8. Kanis J.A., Johansson H., Oden A., and McCloskey E.V. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX((R)). Bone (2009 Feb 28) [Epub ahead of print]
9. McCloskey E.V., Johansson H., Oden A., Vasireddy S., Kayan K., Pande K., Jalava T., and Kanis J.A. Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20 5 (2009) 811-817
10. Kanis J.A., McCloskey E.V., Johansson H., Oden A., Melton III L.J., and Khaltaev N. A reference standard for the description of osteoporosis. Bone 42 3 (2008) 467-475
11. Siris E.S., Chen Y.T., Abbott T.A., Barrett-Connor E., Miller P.D., Wehren L.E., and Berger M.L. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164 10 (2004) 1108-1112
12. McLellan A.R., Gallacher S.J., Fraser M., and McQuillian C. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14 (2003) 1028-1034
13. Chevalley T., Hoffmeyer P., Bonjour J.P., and Rizzoli R. An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int 13 (2002) 450-455
14. van Helden S., Cals J., Kessels F., Brink P., Dinant G.J., and Geusens P. Risk of new clinical fractures within 2 years following a fracture. Osteoporos Int 17 3 (2006) 348-354
15. Lems W.F. Clinical relevance of vertebral fractures. Ann Rheum Dis 66 (2007) 2-4
16. Mackey D.C., Lui L.Y., Cawthon P.M., Bauer D.C., Nevitt M.C., Cauley J.A., Hillier T.A., Lewis C.E., Barrett-Connor E., and Cummings S.R. Study of osteoporotic fractures(sof)and osteoporotic fractures in men study (mros) research groups. high-trauma fractures and low bone mineral density in older women and men. JAMA 298 20 (2007) 2381-2388
17. Sebba A. Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface. Osteoporos Int 20 5 (2009) 675-686
18. Geusens P., Hochberg M.C., van der Voort D.J., Pols H., van der Klift M., Siris E., Melton M.E., Turpin J., Byrnes C., and Ross P. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin proc 77 (2002) 629-637
19. van Staa T.P., Geusens P., Pols H.A., de Laet C., Leufkens H.G., and Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98 (2005) 191-198
20. Available at:. http://www.garvan.org.au/promotions/bone-fracture-risk/
21. Pluijm S.M., Koes B., de Laet C., Van Schoor N.M., Kuchuk N.O., Rivadeneira F., Mackenbach J.P., Lips P., Pols H.A., and Steyerberg E.W. A simple risk score for the assessment of absolute fracture risk in general practice based on two longitudinal studies. J Bone Miner Res. 24 5 (2009) 768-774
22. Rabenda V., Vanoverloop J., Fabri V., Mertens R., Sumkay F., Vannecke C., Deswaef A., Verpooten G.A., and Reginster J.Y. Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am. 90 10 (2008) 2142-2148
23. Cadarette S.M., Katz J.N., Brookhart M.A., Levin R., Stedman M.R., Choudhry N.K., and Solomon D.H. Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. J Rheumatol 35 2 (2008) 319-326
24. Solomon D.H., Finkelstein J.S., Polinski J.M., Arnold M., Licari A., Cabral D., Canning C., Avorn J., and Katz J.N. A randomized controlled trial of mailed osteoporosis education to older adults. Osteoporos Int 17 5 (2006) 760-767
25. Solomon D.H., Katz J.N., Finkelstein J.S., Polinski J.M., Stedman M., Brookhart M.A., Arnold M., Gauthier S., and Avorn J. Osteoporosis improvement: a large-scale randomized controlled trial of patient and primary care physician education. J Bone Miner Res. 22 11 (2007) 1808-1815
26. Morrison L.S., and Tobias J.H. Effect of a case-finding strategy for osteoporosis on bisphosphonate prescribing in primary care. Osteoporos Int 16 1 (2005) 71-77
27. Geusens P., Dumitrescu B., van Geel T., van Helden S., Vanhoof J., and Dinant G.J. Impact of systematic implementation of a clinical case finding strategy on diagnosis and therapy of postmenopausal osteoporosis. J Bone Miner Res. 23 6 (2008) 812-818
28. Tannenbaum C., Clark J., Schwartzman K., Wallenstein S., Lapinski R., Meier D., and Luckey M. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87 (2002) 4431-4437
29. Dumitrescu B., van Helden S., ten Broeke R., Nieuwenhuijzen-Kruseman A., Wyers C., Udrea G., van der Linden S., and Geusens P. Evaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach. BMC Musculoskelet Disord 9 (2008) 109
30. Soe J.T., Vokes T., Broy S.B., Ferrar L., McKiernan F., Roux C., and Binkley N. Vertebral Fracture Assessment: The 2007 ISCD Official Positions. J Clin Densitom 11 1 (2008) 92-108
31. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 12 3 (2008) 157-170
32. Kanis J.A., Johansson H., Oden A., De Laet C., Johnell O., Eisman J.A., Mc Closkey E., Mellstrom D., Pols H., Reeve J., Silman A., and Tenenhouse A. A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int 16 7 (2005) 799-804
33. Holick M.F., and Chen T.C. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87 4 (2008) 1080S-1086S
34. Boonen S., Vanderschueren D., Haentjens P., and Lips P. Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J Intern Med 259 6 (2006) 539-552
35. Boonen S., Lips P., Bouillon R., Bischoff-Ferrari H.A., Vanderschueren D., and Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 92 4 (2007) 1415-1423
36. Bischoff-Ferrari H.A., Dawson-Hughes B., Baron J.A., Burckhardt P., Li R., Spiegelman D., Specker B., Orav J.E., Wong J.B., Staehelin H.B., O'Reilly E., Kiel D.P., and Willett W.C. Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials. Am J Clin Nutr 86 6 (2007) 1780-1790
37. DeLuca H.F. Evolution of our understanding of vitamin D. Nutr Rev 66 10 Suppl. 2 (2008 Oct) S73-S87
38. Bischoff-Ferrari H.A., and Dawson-Hughes B. Where do we stand on vitamin D?. Bone 41 1 Suppl. 1 (2007) S13-S19
39. Heaney R.P. The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 97 1-2 (2005 Oct) 13-19
40. Bischoff-Ferrari H.A. How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 18 4 (2007) 401-407
41. Heaney R.P. Vitamin D: criteria for safety and efficacy. Nutr Rev 66 10 Suppl. 2 (2008) S178-S181
42. Dawson-Hughes B. The role of vitamin D in fracture prevention. BoneKey-Osteovision (2005) 6-10
43. Steingrimsdottir L., Gunnarsson O., Indridason O.S., Franzson L., and Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 294 18 (2005) 2336-2341
44. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Stuck A.E., Staehelin H.B., Orav E.J., Thoma A., Kiel D.P., and Henschkowski J. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 169 6 (2009) 551-561
45. Moayyeri A. The association between physical activity and osteoporotic fractures: a review of the evidence and implications for future research. Ann Epidemiol 18 11 (2008) 827-835
46. Chang J.T., Morton S.C., Rubenstein L.Z., Mojica W.A., Maglione M., Suttorp M.J., Roth E.A., and Shekelle P.G. Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials. BMJ 328 7441 (2004) 680
47. Gillespie L.D., Robertson M.C., Gillespie W.J., Lamb S.E., Gates S., Cumming R.G., and Rowe B.H. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2 (2009 Apr 15) CD007146
48. Parker M.J., Gillespie L.D., and Gillespie W.J. Hip protectors for preventing hip fractures in the elderly. Cochrane Database Syst Rev 4 (2000) CD001255. Review. Update in: Cochrane Database Syst Rev. 2001;(2):CD001255
49. Riggs B.L., and Parfitt A.M. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20 (2005) 177-184
50. Delmas P.D., et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33 (2003) 522-532
51. Delmas P.D., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15 (2004) 792-798
52. Harrington J.T., Ste-Marie L.G., Brandi M.L., Civitelli R., Fardellone P., Grauer A., Barton I., and Boonen S. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74 2 (2004) 129-135
53. Seeman E., et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21 (2006) 1113-1120
54. Hochberg M.C., et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 20 (2005) 971-976
55. Boonen S., et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52 (2004) 1832-1839
56. Marcus R., et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18 (2003) 18-23
57. Lyles K.W., et al. the HORIZON Recurrent Fracture Trial. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med 357 (2007) 1799-1809
58. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., Peacock M., Miller P.D., Lederman S.N., Chesnut C.H., Lain D., Kivitz A.J., Holloway D.L., Zhang C., Peterson M.C., and Bekker P.J. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 8 (2006) 821-831
59. Lewiecki E.M., Miller P.D., McClung M.R., Cohen S.B., Bolognese M.A., Liu Y., Wang A., Siddhanti S., and Fitzpatrick L.A. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 22 12 (2007) 1832-1841 Dmab pg
60. Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B., Austin M., Liu Y., San Martin J., and Amg Bone Loss Study G. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43 2 (2008) 222-229
61. Cummings S., San Martin J., McClung M., Siris E., Eastell R., Reid I.R., Delmas P., Zoog H.B., Austin M., Wang A., Kutilek S., Adami S., Zanchetta J., Libanati C., Siddhanti S., and Christiansen C. FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361 (2009) 756-765
62. Russell R.G. Bisphosphonates: from bench to bedside. Ann NY Acad Sci 1068 (2006) 367-401
63. Greenspan S.L., et al. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 289 (2003) 2525-2533
64. Black D.M., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349 (2003) 1207-1215
65. Finkelstein J.S., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349 (2003) 1216-1226
66. Cosman F., et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353 (2005) 566-575
67. Black D.M., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353 (2005) 555-565
68. Rubin M.R., and Bilezikian J.P. Parathyroid hormone as an anabolic skeletal therapy. Drugs 65 (2005) 2481-2498
69. Warriner A.H., and Curtis J.R. Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol (2009 Apr 30) [Epub ahead of print]
70. Siris E.S., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81 (2006) 1013-1022
71. Siris E.S., Selby P.L., Saag K.G., Borgström F., Herings R.M., and Silverman S.L. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122 2 Suppl (2009 Feb) S3-13
72. Bliuc D., et al. Barriers to effective management of osteoporosis in moderate and minimal trauma fractures: a prospective study. Osteoporos Int 16 (2005) 977-982
73. Penning-van Beest F.J., Erkens J.A., Olson M., and Herings R.M. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 24 5 (2008 May) 1337-1344
74. Martino S., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 (2004) 1751-1761
75. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women, principle results from the women's health initiative randomized controlled trial. J Am Med Assoc 288 (2002) 321-333
76. Epstein S., et al. Disintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacy. J Applied Res 2 (2005) 1-13
77. Ringe J.D., and Möller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int (2009 May 9) [Epub ahead of print]
78. Available at:. www.jbmronline.org/doi/full/10.1359/jbmr.060712
79. Odvina C.V., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294-1301
80. Chapurlat R.D., et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22 (2007) 1502-1509
81. Berenson J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10 (2005) 52-62
82. Cummings S.R., et al. Alendronate and atrial fibrillation. N Engl J Med 356 (2007) 1895-1896
83. Karam R., et al. Letter. N Eng J Med 357 (2007) 712-713
84. Available at:. www.emea.europa.eu./humandocs/PDFs/EPAR/protelos/PressRelease_Protelos_41745807en.pdf Last accessed on 29 December, 2007
85. Vahle J.L., et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32 (2004) 426-438
86. Miller P.D., Delmas P.D., Lindsay R., Watts N.B., Luckey M., Adachi J., Saag K., Greenspan S.L., Seeman E., Boonen S., Meeves S., Lang T.F., and Bilezikian J.P. Open-label study to determine how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide investigators. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93 10 (2008) 3785-3793
87. Díez-Pérez A., and González-Macías J. Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int 19 11 (2008) 1511-1516
88. Lewiecki E.M., and Watts N.B. Assessing response to osteoporosis therapy. Osteoporos Int 19 10 (2008) 1363-1368
89. Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 7 1 (2009) 12-17